IRLAB Therapeutics AB took important steps expanding the development pipeline and nominates a new drug candidate, IRL757, from the P001 discovery program. IRL757 will be developed for the treatment of apathy in people with neurological conditions. Apathy affects between 20% and 80% of people with neurological conditions and currently there is no approved treatment.

Only in the US, apathy is estimated to affect more than 10 million people and their families. IRL757, discovered with IRLAB's discovery platform, ISP, is designed to improve the function of brain areas and neuronal pathways which in many neurological disorders are known to be dysfunctional, leading to apathy and impaired quality of life. IRLAB has initiated studies in preparations of Phase I, including large scale synthesis of the active ingredient which are followed by safety, tolerability and regulatory toxicity studies.

Phase I clinical studies are planned to begin early third quarter, 2023.